Dosing commences for Phase I human clinical trial
Avecho has commenced dosing with a cohort of 16 healthy volunteers for its Australian Phase I Pharmacokinetic (PK) study to characterise the absorption profile of CBD.
The study site, CMAX Clinic in Adelaide, welcomed the volunteers on Saturday 2 October 2021. Dosing will occur at two separate times during a period of two weeks and thereafter, blood samples will be analysed for CBD, TP, T2P and tocopherol (the components of our TPM® formulation).
This is an important milestone in the development of Avecho’s CBD program, providing a first look at the safety and absorption profile of its soft-gel CBD product.